ArticleThe Korean journal of internal medicine2025
The early impact of COVID-19 vaccines on major events in cardiac, pulmonary, and thromboembolic disease: a population-based study.
Article in The Korean journal of internal medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimsAlthough COVID-19 vaccines reduce COVID-19 severity, various safety concerns have emerged. This study, involving a population-based cohort, used health insurance data to investigate potential vaccine-related major outcomes, including cardiac, pulmonary, and thromboembolic diseases.
methodsThis retrospective cohort study involved data from 2,017,884 vaccinated (at least two doses) individuals and 334,583 unvaccinated individuals. The incidences of myocarditis, myocardial infarction, atrial fibrillation, interstitial lung disease, pulmonary thromboembolism, deep vein thrombosis, and cerebrovascular disease were compared between the vaccinated and the unvaccinated groups at 1 week to 3 months after vaccination.
resultsThe study population had a mean age of 54 years (male: 44.6%). Among the vaccinated, 57.7% received the mRNA vaccine only, whereas 35.5% received the adenoviral vector vaccine alone. Multivariate logistic analysis revealed that vaccination was significantly associated with the early development of myocarditis. The mRNA vaccine, a younger age, and retrohyperlipidemia were independent indicators of poor myocarditis prognosis after vaccination. However, the incidence of myocardial infarction at 1-2 weeks post-vaccination, as well as pulmonary thromboembolism and cerebrovascular disease (both at 3 months post-vaccination), were significantly lower in the vaccinated group when compared with the unvaccinated one. However, there was no significant association between vaccination and interstitial lung disease, atrial fibrillation, or deep vein thrombosis.
conclusionThe younger male population (age: < 45 years) should be cautious about receiving the COVID-19 mRNA vaccine and should be closely monitored for myocarditis after vaccination. Vaccination was associated with short-term protection against venous and arterial thrombotic events, as well as hemorrhagic events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.